Prevention of infection and bleeding in leukemic patients receiving intensive remission maintenance therapy.
Leukemic patients were treated with intensive chemotherapy to reduce the number of leukemic cells remaining after complete remission was induced. This therapy resulted in periods of severe granulocytopenia and thrombocytopenia. Considering 13 patients who did not receive antibacterial prophylaxis, documented infection was quite common including four episodes of bacteremia and three urinary tract infections. By contrast, patients who received co-trimoxazole as antibacterial prophylaxis experienced one half as many febrile episodes and no serious infections. Prophylactic co-trimoxazole is beneficial for patients with marrow remission in this study. Similar benefit in patients with leukemic marrows remains to be established. All patients received prophylactic platelet transfusion three times a week when their platelet counts were less than 20,000/microliter. There were no episodes of bleeding other than petechiae.
D000328:Adult; D000368:Aged; D000380:Agranulocytosis / Q000209:etiology; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001424:Bacterial Infections / Q000188:drug therapy* / Q000517:prevention & control; D004338:Drug Combinations / Q000627:therapeutic use; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D013411:Sulfadiazine / Q000627:therapeutic use*; D013921:Thrombocytopenia / Q000209:etiology; D014295:Trimethoprim / Q000627:therapeutic use*; D000096926:Benzenesulfonamides
D000970:Antineoplastic Agents; D004338:Drug Combinations; D013411:Sulfadiazine; D014295:Trimethoprim; C024873:sulfadiazine, trimethoprim drug combination; D000096926:Benzenesulfonamides